Thursday, March 23, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

H7N9 Influenza Rapid Detection Test Authorized for Emergency Use

by Global Biodefense Staff
May 1, 2014

H7N9 Influenza virus. Image courtesy of CDC.

Arbor Vita Corporation (AVC), a privately held company, announced this week that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for their A/H7N9 Influenza Rapid Test for the presumptive detection of the influenza A/H7N9 virus (detected in China in 2013) in patients with signs and symptoms of respiratory infection in conjunction with epidemiological risk factors.

The new strain of the avian influenza virus first appeared in China in 2013.  This particular ‘bird flu’, influenza A/H7N9 virus, kills one in three people infected.  In two successive and increasing waves, this virus has moved across China and crossed the Chinese border into Hong Kong, Taiwan and Malaysia. As recently as last week, another case of influenza A/H7N9 virus was reported in Hong Kong.

The U.S. Navy first approached Arbor Vita in the spring of 2013 to develop a simple, accurate test to detect the influenza A/H7N9 virus. Arbor Vita had demonstrated success in developing similar testing for the influenza A/H5N1 virus.

Collaborators at the US Navy, Swiss Armed Forces (Spiez Laboratory) and the University of Hong Kong evaluated AVC A/H7N9 Influenza Rapid Test. “We have confirmed that Arbor Vita’s test can detect human H7N9 viruses. The dual testing system – Influenza A virus and A/H7N9 virus – clearly has a great advantage.” says Dr. Leo Poon, associate professor at Centre of Influenza Research and School of Public Health, University of Hong Kong.

“We are delighted to participate to make this surveillance tool available for pre-pandemic setting to help prevent a lethal pandemic,” says Colonel Sergei Bankoul, MD, Senior Consultant to the Swiss Surgeon General.

Access to the influenza A/H7N9 virus proved to be difficult but possible with help from Dr. Leo Poon. Cases of influenza A/H7N9 virus around the Lunar New Year mushroomed as people travelled to visit each other bringing live chickens as presents from affected areas and spreading the virus inside and outside of China.

“The AVC A/H7N9 Influenza Rapid Test is a potent early surveillance tool. This test is suitable for early, point of care screening in strategic locations such as borders checks, airports, US company clinics in China, etc. Early detected infections are then confirmed by molecular tests, such as PCR in large reference laboratories,” says Dr. Peter Lu, Chief Executive Officer of Arbor Vita Corporation.

“We are proud and excited to receive FDA’s authorization under an EUA for the first rapid test able to diagnose patients suffering from this deadly respiratory infection. We applaud the FDA’s efforts to authorize the test. This test may prove to be critical at containing a potential avian influenza pandemic” concludes Dr. Peter Lu.

The test has additionally been authorized by the DoD network laboratories for use in the US and outside the US, other US government laboratories outside the US, or foreign laboratories.

Source: Arbor Vita Corporation press release, adapted.

Tags: Avian InfluenzaEmergency Use AuthorizationH7N9InfluenzaPandemicPOC Diagnostics

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC